Sitagliptin: A review of its use in the management of type 2 diabetes mellitus

Drugs

Volumn 70, Issue 4, 2010, Pages 489-512

  Dhillon, Sohita ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; CYCLOSPORIN; DIGOXIN; EXENDIN 4; GLACTIV; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; NATEGLINIDE; NORETHISTERONE; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SIMVASTATIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TESAVEL; UNCLASSIFIED DRUG; VILDAGLIPTIN; VOGLIBOSE; WARFARIN;

ABDOMINAL PAIN; ACUTE PANCREATITIS; AREA UNDER THE CURVE; B LYMPHOCYTE; CHRONIC PANCREATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; PYRAZINES; TRIAZOLES;

EID: 77949285419     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11203790-000000000-00000     Document Type: Review

References (90)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009 Jan; 32 Suppl. 1: S62-7
2. World Health Organization. Diabetes: what is diabetes? [online]. Available from URL: http://www.who.int/med iacentre/factsheets/fs312/en/ [Accessed 2009 Sep 25]
3. Rosenstock J, Zinman B. Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2007 Apr; 14 (2): 98-107
4. Campbell RK. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus. Ann Pharmacother 2007 Jan; 41 (1): 51-60
5. Ahren B. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care 2007 Jun; 30 (6): 1344-1350
6. Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes: part II. Incretin-based therapy and beyond. Circulation 2008 Jan 29; 117 (4): 574-584
7. Lyseng-Williamson KA. Sitagliptin. Drugs 2007; 67 (4): 587-97
8. Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3(trifluoromethyl)-5,6- dihydro [1,2,4] triazolo [4,3-a] pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005 Jan 13; 48 (1): 141-151
9. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006 Nov; 91 (11): 4612-4619
10. Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005 Dec; 78 (6): 675-688
11. Bergman AJ, Stevens C, Zhou YY, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006 Jan; 28 (1): 55-72
12. Herman GA, Bergman A, Liu F, et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 2006 Aug; 46 (8): 876-886
13. Migoya EM, Miller JL, Larson PJ, et al. Sitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase active GLP-1 concentrations [abstract no. 0111]. Diabetologia 2007; 50 Suppl. 1: S52
14. Alba M, Sheng D, Guan Y, et al. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement. Curr Med Res Opin 2009 Oct; 25 (10): 2507-2514
15. Nonaka K, Tsubouchi H, Okuyama K, et al. Effects of oncedaily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus. Horm Metab Res 2009 Mar; 41 (3): 232-237
16. Kasper A, Vilsbøll T, Knop FK, et al. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, improves the insulin secreting capacity of the (3-cells in subjects with type 2 diabetes mellitus: a randomized trial [abstract no. 605-P]. 69th Scientific Sessions of the American Diabetes Association; 2009 Jun 5-9; New Orleans (LA)
17. Brazg R, Xu L, Dalla Man C, et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h gly-caemic control and [3-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9 (2): 186-193
18. Marfella R, Barbieri M, Grella R, et al. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complications. Epub 2009 Mar 3
19. DeFronzo RA, Okerson T, Viswanathan P, et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008 Oct; 24 (10): 2943-2952
20. Bloomfield DM, Krishna R, Hreniuk D, et al. A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects. J Clin Pharmacol 2009 Aug; 49 (8): 937-946
21. Bergman A, Mistry GC, Luo WL, et al. Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos 2007 Sep; 28 (6): 307-313 (Pubitemid 47439636)
22. Bergman A, Ebel D, Liu F, et al. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos 2007 Sep; 28 (6): 315-322
23. Merck & Co., Inc. Januvia™ (sitagliptin phosphate) tablets: US prescribing information [online]. Available from URL: http://www.accessdata.fda. gov/drugsatfda-docs/label/2009/ 021995s013lbl.pdf [Accessed 2010 Jan 26].
24. 14C]sitagliptin in humans. Drug Metab Dispos 2007; 35 (4): 533-538
25. Bergman A, Stevens C, Yi B, et al. Lack of a clinically meaningful effect on age, gender or obesity on the pharmacokinetics of the DPP-IV inhibitor MK-0431 [abstract no. 2101-PO]. Diabetes 2005 Jun; 54 Suppl. 1: A506
26. Migoya EM, Stevens CH, Bergman AJ, et al. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol 2009 Winter; 16 (1): e165-70
27. Bergman AJ, Cote J, Yi B, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007 Jul; 30 (7): 1862-1864
28. Mistry GC, Bergman AJ, Zheng W, et al. Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. Br J Clin Pharmacol 2008 Jul; 66 (1): 36-42
29. Glactiv® (sitagliptin phosphate hydrate tablets): Japanese prescribing information. Osaka: Ono Pharmaceutical Co., Ltd. 2009.
30. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006 Dec; 29 (12): 2632-2637
31. Mohan V, Yang W, Son HY, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 2009 Jan; 83 (1): 106-116
32. Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008 Feb; 79 (2): 291-298
33. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49 (11): 2564-2571
34. Aschner P, Katzeff HL, Guo H, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010 Mar 1; 12 (3): 252-261
35. Iwamoto Y, Tajima N, Kadowaki K, et al. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab. Epub 2010 Jan 7
36. Barzilai N, Mahoney EM, Guo H, et al. Sitagliptin is well tolerated and leads to rapid improvement in blood glucose in the first days of monotherapy in patients aged 65 years and older with T2DM [abstract no. 587-P plus poster]. 69th Scientific Sessions of the American Diabetes Association; 2009 Jun 5-9; New Orleans (LA)
37. Chan JC, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008 Jul; 10 (7): 545-555
38. Aschner P, Lunceford J, Williams-Herman D. Once-daily sitagliptin monotherapy provides effective glycemic control over 54 weeks and is well tolerated in patients with type 2 diabetes [abstract no. 2181-PO]. 67th Scientific Sessions of the American Diabetes Association; 2007 Jun 22-26; Chicago (IL)
39. Goldstein BJ, Feinglos MN, Lunceford JK, et al. on behalf of the sitagliptin 036 study group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007 Aug; 30 (8): 1979-1987
40. Yoon KH, Shockey JR, Temg R, et al. Initial combination therapy with sitagliptin and pioglitazone improves glycaemic control and measure of b-cell function compared with piogli-tazone alone in patients with type 2 diabetes [abstract no. 522-P plus poster]. 69th Scientific Sessions of the American Diabetes Association; 2009 Jun 5-9; New Orleans (LA)
41. Charbonnel B, Karasik A, Liu J, et al. on behalf of the sitagliptin study 020 group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006 Dec; 29 (12): 2638-2643
42. Kadowaki T, Tajima N, Odawara M, et al. Sitagliptin added to ongoing treatment with metformin improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes [abstract no. 2135-PO]. Diabetes 2008 Jun; 57 Suppl. 1: A589-590
43. Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy inpatients with type 2 diabetes. Curr Med Res Opin 2008 Feb; 24 (2): 537-550
44. Nauck MA, Meininger G, Sheng D, et al. on behalf of the sitagliptin study 024 group. Efficacy and safety of the di-peptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007 Mar; 9 (2): 194-205
45. Scott R, Loeys T, Davies MJ, et al. on behalf of the sitagliptin study 801 group. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008 Sep; 10 (10): 959-969
46. Dobs A, Goldstein BJ, Wieczorek L, et al. Triple combination therapy with sitagliptin, metformin, and rosiglitazone improver glyemic control in patients with type 2 diabetes [abstract no. 2152-PO]. 68th Scientific Sessions of the American Diabetes Association; 2008 Jun 6-10; San Francisco (CA)
47. Kashiwagi A, Tajima N, Kadowaki T, et al. Sitagliptin added to ongoing treatment with pioglitazone improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes [abstract no. 2136-PO]. Diabetes 2008; 57 Suppl. 1: A590
48. Rosenstock J, Brazg R, Andryuk PJ, et al. on behalf of the sitagliptin study 019 group. Efficacy and safety of the dipepti-dyl peptidase-4 inhibitor sitagliptin added to ongoing piogli-tazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006 Oct; 28 (10): 1556-1568
49. Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007 Sep; 9 (5): 733-745
50. Tajima N, Kadowaki T, Odawara M, et al. Sitagliptin added to ongoing treatment with glimepiride improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes [abstract no. 2134-PO]. Diabetes 2008; 57 Suppl. 1: A589
51. Vilsbøll T, Rosenstock J, Yki-Jarvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010 Feb; 12 (2): 167-177
52. Derosa G, Maffioli P, Salvadeo SA, et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism. Epub 2009 Dec 14
53. Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin 2009 Mar; 25 (3): 569-583
54. Qi DS, Teng R, Jiang M, et al. Two-year treatment with sitagliptin and initial combination therapy of sitagliptin and metformin provides substantial and durable glycaemic control in patients with type 2 diabetes [abstract no. 73]. Diabetologia 2008; 51 Suppl. 1: S36
55. Karasik A, Wu M, Williams-Herman D, et al. Sitagliptin added to ongoing metformin therapy provides sustained glycemic control over 54 weeks, with a low incidence of hypoglycemia and with weight loss [abstract no. 523-P]. 67th Scientific Sessions of the American Diabetes Association; 2007 Jun 22-26; Chicago (IL)
56. Maegawa H, Kashiwagi A, Tajima N, et al. Sitagliptin added to ongoing treatment with pioglitazone study up to 52 weeks in Japanese patients with T2DM [abstract no. 910]. Diabetologia 2008; 51 Suppl. 1: S365
57. Iwamoto Y, Nonaka K, Okada A, et al. Dose-response relationship for glycaemic efficacy, safety and tolerability of sitagliptin after 12 weeks of treatment in Japanese patients with type 2 diabetes mellitus [abstract no. 0888 plus poster]. Diabetologia 2007 Sep; 50 Suppl. 1: S366.
58. Plus poster presented at the 43rd Annual Meeting of the European Association for the Study of Diabetes; 2007 Sep 18-21; Amsterdam
59. Hanefeld M, Herman GA, Wu M, et al. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin 2007 Jun; 23 (6): 1329-1339
60. Scott R, Wu M, Sanchez M, et al. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as mono-therapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007 Jan; 61 (1): 171-180 (Pubitemid 46269371)
61. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care 2009 Jan; 32 Suppl. 1: S13-61
62. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med. 2006;Jun; 23; 6: 579-593.
63. Merck. Monotherapy study in patients with type 2 diabetes mellitus [ClinicalTrials.gov identifier NCT00087516]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Feb 23].
64. ClinicalTrials.gov. Initial combination with pioglitazone study [online]. Available from URL: http://clinicaltrials. gov/ct2/show/results/NCT00397631 [Accessed 2010 Jan 26].
65. Williams-Herman D, Round E, Swern AS, et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord 2008; 8: 14
66. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metfor-min or glyburide. Curr Med Res Opin 2009 Apr; 25 (4): 1019-1027
67. European Medicines Agency. Januvia (sitagliptin) filmcoated tablets: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/human docs/PDFs/EPAR/januvia/emea-combined-h722en.pdf [Accessed 2010 Jan 26]
68. US FDA. Information for Healthcare Professionals: acute pancreatitis and sitagliptin (marketed as Januvia and Janumet) [online]. Available from URL: http://www.fda. gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor PatientsandProviders/DrugSafetyInformationforHeathcarePro fessionals/ucm183768. htm [Accessed 2010 Jan 26]
69. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007 Jan 2; 115 (1): 114-126
70. International Diabetes Federation. Complications of diabetes [online]. Available from URL: http://www.idf.org/node/ 1051?unode=3B968870-C026-2FD3- 879E38D367DD9E92 [Accessed 2009 Sep 28]
71. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 Jun 12; 358 (24): 2554-2559
72. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 Jun 12; 358 (24): 2560-2572
73. UK Prospective Diabetes Study Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published erratum appears in Lancet 1998 Nov 7; 352 (9139): 1558]. Lancet. 1998; Sep 12;;352;9131:837-853.
74. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 Oct 9; 359 (15): 1577-1589
75. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009 Jan 20; 53 (3): 298-304
76. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009 Jan; 32 (1): 193-203
77. National Institute of Health and Clinical Excellence. Type 2 diabetes: full guideline (CG66) [online]. Available from URL: http://guidance.nice.org.uk/ CG66/Guidance/pdf/ English [Accessed 2009 Dec 4]
78. National Institute of Health and Clinical Excellence. Type 2 diabetes: newer agents (CG87, partial update of CG66) [online]. Available from URL: http://guidance.nice.org.uk/ CG87 [Accessed 2009 Dec 4].
79. Barnett AH. New treatments in type 2 diabetes: a focus on the incretin-based therapies. Clin Endocrinol (Oxf) 2009 Mar; 70 (3): 343-353
80. Pratley RE, Gilbert M. Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud 2008 Summer; 5 (2): 73-94
81. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007 Jul 11; 298 (2): 194-206 (Pubitemid 47057766)
82. Wajchenberg BL. b-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007 Apr; 28 (2): 187-218
83. Riche DM, East HE, Riche KD. Impact of sitagliptin on markers of beta-cell function: a meta-analysis. Am J Med Sci 2009 May; 337 (5): 321-328
84. Bethel MA, Gree J, Califf RM, et al. Rationale and design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) [abstract no. 2152-PO]. 69th Scientific Sessions of the American Diabetes Association; 2009 Jun 5-9; New Orleans (LA)
85. Merck. Sitagliptin cardiovascular outcome study (TECOS) [ClinicalTrials.gov identifier NCT00790205]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2009 Dec 2]
86. Schwarz B, Gouveia M, Chen J, et al. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obes Metab 2008 Jun; 10 Suppl. 1: 43-55
87. Brandle M, Chen J, Alemao E, et al. Cost-effectiveness of adding sitagliptin vs. an sulfonylurea in Swiss patients with type 2 diabetes inadequately controlled on metformin monotherapy [abstract no. 1095]. Diabetologia 2008; 51 Suppl. 1: S446
88. Minshall M, St. Charles M, Pandya B, et al. The costeffectiveness of pioglitazone compared with sitagliptin: an economic evaluation using a validated economic model from a third party payer perspective in the USA [abstract no. PDB19]. Value Health 2007 Nov/Dec; 10 (6): A259
89. Ahren B. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin-diabetes control and potential adverse events. Best Pract Res Clin Endocrinol Metab 2009 Aug; 23 (4): 487-498
90. Merck Sharp and Dohme. Januvia receives approval for add-on to insulin in the EU [media release]. 19 Nov 2009 [online]. Available from URL: http://www.nelm.nhs.uk/ en/Categories/Medicines-Information/445422/445850/